Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) is a potent and specific post-transcriptional gene silencing process. Since its discovery, tremendous efforts have been made to translate RNAi technology into therapeutic applications for the treatment of different human diseases including respiratory diseases, by manipulating the expression of disease-associated gene(s). Similar to other nucleic acid-based therapeutics, the major hurdle of RNAi therapy is delivery. Pulmonary delivery is a promising approach of delivering RNAi therapeutics directly to the airways for treating local conditions and minimizing systemic side effects. It is a non-invasive route of administration that is generally well accepted by patients. However, pulmonary drug delivery is a challenge as the lungs pose a series of anatomical, physiological and immunological barriers to drug delivery. Understanding these barriers is essential for the development an effective RNA delivery system. In this review, the different barriers to pulmonary drug delivery are introduced. The potential of RNAi molecules as new class of therapeutics, and the latest preclinical and clinical studies of using RNAi therapeutics in different respiratory conditions are discussed in details. We hope this review can provide some useful insights for moving inhaled RNAi therapeutics from bench to bedside.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
The Acute Respiratory Distress Syndrome
Ware, L. B., & Matthay, M. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421806 · Cited by 4,666
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926 · cited 1×
“Although these medications can manage the conditions in most of the patients, there are still challenges of poor patient compliance, intolerability and long term adverse effects [179].”
BackgroundNF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918 · cited 1×
“NF-κB plays a key role in the expression of many pro-inflammatory proteins [191].”
BackgroundNon-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · cited 1×
“RNAi delivery system can be categorized into viral and non-viral vectors according to their nature, and these delivery systems have been extensively reviewed [63] [64] [65] [66] [67] .”
BackgroundToxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286 · cited 1×
“efficacy, the major challenges of using the lipids are the immune response and cytotoxicity [79].”
BackgroundDelivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
The acute respiratory distress syndrome
Matthay, M. A., Ware, L. B., & Zimmerman, G. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60331 · Cited by 1,706 · cited 1×
“Its pathological changes include the release of pro-inflammatory cytokines and chemokines, and the destruction of the epithelium-capillary interface; the latter can facilitate the extravasation of protein-rich fluid and the infiltration of neutrophils, thereby exacerbating the condition [213, 214] .”
BackgroundGilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Endosomal escape pathways for delivery of biologicals
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.004 · Cited by 1,561 · cited 1×
“Strategies of endosomal escape have been reviewed in other literatures [58] [59] [60] [61] .”
BackgroundTGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401 · cited 1×
“It has a role in tumor suppression as suggested by the finding that specific inhibition of TGF-β in mouse stromal fibroblasts results in spontaneous carcinoma formation in the adjacent epithelium [226] .”
BackgroundsiRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081 · cited 1×
“The pre-miRNA is subsequently transported to the cytoplasm by Exp5, and is processed by the Dicer into mature miRNA of 18–25 nucleotides in length [21].”
BackgroundSelf-citationInfluence of particle size on regional lung deposition – What evidence is there?
Carvalho, T. C., Peters, J. I., & Williams III, R. O. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.040 · Cited by 614
Clathrin-independent pathways of endocytosis
Mayor, S., Parton, R. G., & Donaldson, J. G. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016758 · Cited by 525
Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease
Edwards, M. R., Bartlett, N. W., Clarke, D., Birrell, M., Belvisi, M., & Johnston, S. L. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.003 · Cited by 375 · cited 3×
“Inhibition of NF-κB pathway in the lungs was reported to be beneficial in asthma model [176, 192] .”
BackgroundMethodInfluentialSakagami, M. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.012 · Cited by 331 · cited 1×
“The optimal particle size for lung deposition is between 1 and 5 μm [35,36].”
BackgroundCo-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles
Li, L., Gu, W., Chen, J., Chen, W., & Xu, Z. P. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.095 · Cited by 304
High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation
Zhao, Y., Zheng, Z., Cohen, C. J., Gattinoni, L., Palmer, D. C., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.688 · Cited by 283 · cited 1×
“Effective T cells transfection in vitro was achieved by electroporation [219], an approach that is not clinically feasible.”
BackgroundMicroRNA-155 Promotes Autophagy to Eliminate Intracellular Mycobacteria by Targeting Rheb
Wang, J., Yang, K., Zhou, L., MinhaoWu, Wu, Y., Zhu, M., Lai, X., Chen, T., Feng, L., Li, M., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003697 · Cited by 265
Bacterial Complications of Respiratory Tract Viral Illness: A Comprehensive Evaluation
Falsey, A. R., Becker, K. L., Swinburne, A. J., Nylen, E. S., Formica, M. A., Hennessey, P. A., Criddle, M. M., Peterson, D. R., Baran, A., & Walsh, E. E. (2013) · Journal of Infectious Diseases · doi:10.1093/infdis/jit190 · Cited by 159 · cited 1×
“It is one of the most common reasons for hospitalization among adults [121].”
BackgroundLentiviral-mediated GATA-3 RNAi decreases allergic airway inflammation and hyperresponsiveness
Lee, C.-C., Huang, H.-Y., & Chiang, B.-L. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300309 · Cited by 70 · cited 5×
“Many transcription factors including nuclear factor-κB (NF-κB) [168], signal transducer and activator of transcription factor 6 (STAT6) [166] and GATA-binding protein 3 (GATA3) [170] are involved in the production Th2 cytokine in the airways of patients with asthma.”
BackgroundResultInfluential
Cited by
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Mehta, M., Deeksha, Tewari, D., Gupta, G., Awasthi, R., Singh, H., Pandey, P., Chellappan, D. K., Wadhwa, R., Collet, T., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.05.028 · Cited by 397
Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome
Zoulikha, M., Xiao, Q., Boafo, G. F., Sallam, M. A., Chen, Z., & He, W. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.009 · Cited by 275
Oligonucleotide therapies for disorders of the nervous system
Khorkova, O., & Wahlestedt, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3784 · Cited by 179
Metadata
- Authors
- Qiu, Y., Lam, J., Leung, S., & Liang, W.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2016-09-20
- Volume
- 21
- Issue
- 9
- Pages
- 1249
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2523101278
- Cited by
- 69
- References
- 21
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.